[德国新诊断的乙型和丙型肝炎病例因筛查而显著增加]。

IF 1.4 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY
Zeitschrift fur Gastroenterologie Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI:10.1055/a-2435-5069
Dietrich Hüppe, Yvonne Serfert, Markus Cornberg, Heiner Wedemeyer
{"title":"[德国新诊断的乙型和丙型肝炎病例因筛查而显著增加]。","authors":"Dietrich Hüppe, Yvonne Serfert, Markus Cornberg, Heiner Wedemeyer","doi":"10.1055/a-2435-5069","DOIUrl":null,"url":null,"abstract":"<p><p>In 2016, the World Health Organization (WHO) decided on an initiative to identify 90% of the world's existing hepatitis B and C virus infections by 2030, treat 80% and reduce the mortality by 65%. In 2016, the federal government endorsed these goals. From Oct 1, 2021, the G-BA included a one-time screening for hepatitis B and C in the health examination (GU) for people aged 35 and over who have statutory health insurance. The previous participation rates in the GU were evaluated and the effectiveness of the program is documented using the reporting data on hepatitis B and C of Robert Koch Institute (RKI).Notifications from Central Institute of Statutory Health Insurance (ZI) and Scientific Institute of the local health insurance companies (WIdO) were compiled with regard to the GU, the reporting data from the RKI were collected and analyzed using SURVSTAT@RKI 2.0 as well as billing data from the Association of Statutory Health Insurance Physicians (KBV).Between 2007 and 2021, around 83% of all insured persons took part in a GU at least once. From the fourth quarter of 2021, the number of newly diagnosed cases of hepatitis B and C increased. In 2022, the increase for hepatitis B was 91.9% and for hepatitis C 68%. This trend continued in 2023, with new diagnoses of hepatitis B increasing by 160% (to 22,795 cases) and hepatitis C increasing by 121% (to 10,508 cases) compared to 2021. The analysis of the KBV billing data showed that the increase in new diagnoses shows a strong correlation between the number of new diagnoses within the GU and the total number of diagnoses.The decision of the Federal Joint Committee (G-BA) to include hepatitis B and C screening in the GU seems to be a success in detecting previously undetected cases of the disease. Based on the billing data from the KBV, a high level of agreement could be demonstrated between the number of new diagnoses within the GU and the increase in the total number of diagnoses. The goals of the WHO may be achievable.</p>","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"31-38"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Significant increase in newly diagnosed hepatitis B and C cases in Germany due to screening].\",\"authors\":\"Dietrich Hüppe, Yvonne Serfert, Markus Cornberg, Heiner Wedemeyer\",\"doi\":\"10.1055/a-2435-5069\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In 2016, the World Health Organization (WHO) decided on an initiative to identify 90% of the world's existing hepatitis B and C virus infections by 2030, treat 80% and reduce the mortality by 65%. In 2016, the federal government endorsed these goals. From Oct 1, 2021, the G-BA included a one-time screening for hepatitis B and C in the health examination (GU) for people aged 35 and over who have statutory health insurance. The previous participation rates in the GU were evaluated and the effectiveness of the program is documented using the reporting data on hepatitis B and C of Robert Koch Institute (RKI).Notifications from Central Institute of Statutory Health Insurance (ZI) and Scientific Institute of the local health insurance companies (WIdO) were compiled with regard to the GU, the reporting data from the RKI were collected and analyzed using SURVSTAT@RKI 2.0 as well as billing data from the Association of Statutory Health Insurance Physicians (KBV).Between 2007 and 2021, around 83% of all insured persons took part in a GU at least once. From the fourth quarter of 2021, the number of newly diagnosed cases of hepatitis B and C increased. In 2022, the increase for hepatitis B was 91.9% and for hepatitis C 68%. This trend continued in 2023, with new diagnoses of hepatitis B increasing by 160% (to 22,795 cases) and hepatitis C increasing by 121% (to 10,508 cases) compared to 2021. The analysis of the KBV billing data showed that the increase in new diagnoses shows a strong correlation between the number of new diagnoses within the GU and the total number of diagnoses.The decision of the Federal Joint Committee (G-BA) to include hepatitis B and C screening in the GU seems to be a success in detecting previously undetected cases of the disease. Based on the billing data from the KBV, a high level of agreement could be demonstrated between the number of new diagnoses within the GU and the increase in the total number of diagnoses. The goals of the WHO may be achievable.</p>\",\"PeriodicalId\":23853,\"journal\":{\"name\":\"Zeitschrift fur Gastroenterologie\",\"volume\":\" \",\"pages\":\"31-38\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zeitschrift fur Gastroenterologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2435-5069\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur Gastroenterologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2435-5069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2016 年,世界卫生组织(WHO)决定采取一项举措,在 2030 年前发现全球 90% 的现有乙型和丙型肝炎病毒感染者,治疗 80%,并将死亡率降低 65%。2016 年,联邦政府批准了这些目标。自 2021 年 10 月 1 日起,G-BA 将在 35 岁及以上拥有法定医疗保险的人群的健康检查(GU)中加入一次性乙型和丙型肝炎筛查。通过罗伯特-科赫研究所(RKI)的乙型肝炎和丙型肝炎报告数据,对以往的健康检查参与率进行了评估,并记录了该计划的有效性。我们汇编了法定医疗保险中央研究所(ZI)和地方医疗保险公司科学研究所(WIdO)有关 GU 的通知,并使用 SURVSTAT@RKI 2.0 收集和分析了 RKI 的报告数据以及法定医疗保险医生协会(KBV)的账单数据。从 2021 年第四季度开始,新确诊的乙型肝炎和丙型肝炎病例数量有所增加。2022 年,乙型肝炎病例增加了 91.9%,丙型肝炎病例增加了 68%。这一趋势在 2023 年仍在继续,与 2021 年相比,乙型肝炎新诊断病例增加了 160%(达到 22,795 例),丙型肝炎增加了 121%(达到 10,508 例)。对 KBV 账单数据的分析表明,新诊断病例的增加表明,GU 内新诊断病例数与诊断病例总数之间存在很强的相关性。联邦联合委员会(G-BA)决定将乙型肝炎和丙型肝炎筛查纳入 GU,这似乎成功地发现了以前未被发现的疾病病例。联邦联合委员会(G-BA)将乙型肝炎和丙型肝炎筛查纳入 GU 的决定似乎成功地发现了以前未被发现的病例。根据 KBV 的账单数据,GU 新诊断病例数与诊断病例总数的增长之间存在高度的一致性。世卫组织的目标是可以实现的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Significant increase in newly diagnosed hepatitis B and C cases in Germany due to screening].

In 2016, the World Health Organization (WHO) decided on an initiative to identify 90% of the world's existing hepatitis B and C virus infections by 2030, treat 80% and reduce the mortality by 65%. In 2016, the federal government endorsed these goals. From Oct 1, 2021, the G-BA included a one-time screening for hepatitis B and C in the health examination (GU) for people aged 35 and over who have statutory health insurance. The previous participation rates in the GU were evaluated and the effectiveness of the program is documented using the reporting data on hepatitis B and C of Robert Koch Institute (RKI).Notifications from Central Institute of Statutory Health Insurance (ZI) and Scientific Institute of the local health insurance companies (WIdO) were compiled with regard to the GU, the reporting data from the RKI were collected and analyzed using SURVSTAT@RKI 2.0 as well as billing data from the Association of Statutory Health Insurance Physicians (KBV).Between 2007 and 2021, around 83% of all insured persons took part in a GU at least once. From the fourth quarter of 2021, the number of newly diagnosed cases of hepatitis B and C increased. In 2022, the increase for hepatitis B was 91.9% and for hepatitis C 68%. This trend continued in 2023, with new diagnoses of hepatitis B increasing by 160% (to 22,795 cases) and hepatitis C increasing by 121% (to 10,508 cases) compared to 2021. The analysis of the KBV billing data showed that the increase in new diagnoses shows a strong correlation between the number of new diagnoses within the GU and the total number of diagnoses.The decision of the Federal Joint Committee (G-BA) to include hepatitis B and C screening in the GU seems to be a success in detecting previously undetected cases of the disease. Based on the billing data from the KBV, a high level of agreement could be demonstrated between the number of new diagnoses within the GU and the increase in the total number of diagnoses. The goals of the WHO may be achievable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Zeitschrift fur Gastroenterologie
Zeitschrift fur Gastroenterologie 医学-胃肠肝病学
CiteScore
1.40
自引率
15.40%
发文量
562
审稿时长
6-12 weeks
期刊介绍: Die Zeitschrift für Gastroenterologie ist seit über 50 Jahren die führende deutsche Fachzeitschrift auf dem Gebiet der Gastroenterologie. Sie richtet sich an Gastroenterologen und alle anderen gastroenterologisch interessierten Ärzte. Als offizielles Organ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten sowie der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie informiert sie zuverlässig und aktuell über die wichtigen Neuerungen und Entwicklungen in der Gastroenterologie.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信